https://www.fool.com/investing/2019/01/15/why-abiomed-stock-gained-734-in-2018.aspx
Short article on Abiomed. Only 10% penetration of addressable market thus far in the US. The growth potential in the US alone is massive, and that is excluding international growth.
This should really bode well for Sensera as long as we remain sticky and supply the sensor for all future iterations of the Impella.
Ann: Sensera Working Capital Financing to Support Revenue Growth, page-10
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
